GlassScriptPhysician profile
Tammy J Hill
NPI 1831172170
$1,725.44
in general payments reported to CMS, 2019-2025
20 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.32 · 2022: $484 · 2023: $418 · 2024: $577 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $251.11 | 2022-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $219.58 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $209.85 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.70 | 2022-2025 | Jardiance |
| Abbvie INC. | $133.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $129.08 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $121.08 | 2022 | |
| Lilly USA, LLC | $118.04 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $74.19 | 2023-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.70 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $47.40 | 2023-2024 | |
| Pfizer INC. | $38.97 | 2022-2024 | |
| Amgen INC. | $34.65 | 2022-2023 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $29.82 | 2024-2025 | Voquezna |
| Agios Pharmaceuticals, INC. | $23.42 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.35 | 2021 | |
| Mylan Specialty L.P. | $16.33 | 2023 | Yupelri |
| Astellas Pharma US INC | $13.89 | 2024 | Veozah |
| Exact Sciences Corporation | $13.65 | 2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.